Despite the ongoing pandemic, Cancer is expected to become the leading cause of death in the U.S., with more than 600,000 deaths expected in 2021. Unfortunately, cancer touches nearly everyone and often is detected too late. Recommended screening tests save lives, but only cover five cancer types in the U.S. and screen for a single cancer at a time. In fact, cancers responsible for 71% of cancer deaths in the U.S. have no recommended early detection screening.
Representing a groundbreaking innovation in cancer detection technology, the Galleri test screens for multiple cancers, even at early stages. In a clinical study, Galleri demonstrated the ability to detect more than 50 types of cancer — over 45 of which lack recommended screening tests today in the U.S. — with a low false positive rate of less than 1%. When a cancer signal is detected, Galleri can determine where in the body the cancer is located with high accuracy.
Megan P. Hall, PhD, Senior Director of Medical Communications in Medical Affairs at GRAIL, Inc, discusses the importance of early detection, and how new technology, like Galleri, can help save lives.